Modern’a redacted vaccine candidate cleared for phase 2


Moderna (NASDAQ:) says the FDA has given the green light to begin the Phase 2 study on its redacted redacted vaccine (mRNA-1273).

It’s expected to start imminently, with the goal of a Phase 3 study to begin in early summer, and approval as soon as 2021.

This is important because Moderna is ahead of everyone else in the redacted vaccine battle.

Leave a Reply